caa a22 4500 606158340 CHVBK 20210128100618.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10557-015-6624-3 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6624-3 Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial [Elektronische Daten] [Lidia Staszewsky, Serge Masson, Simona Barlera, Marcello Disertori, Silvana Boni, Daniele Bertoli, Olga Vriz, Elena Pasotti, Prisca Zeni, Tarcisio Vago, Aldo Maggioni, Gianni Tognoni, Roberto Latini] Purpose: Atrial fibrillation (AF) is the most common arrhythmia and has an increasing impact on public health because of its morbidity and mortality. Clinical and diagnostic tests to predict the recurrence of arrhythmia and clinical events before AF becomes permanent are still an open issue. Methods: 307 out of 1442 patients in sinus rhythm, at high risk of recurrence of AF enrolled in the GISSI-AF study, participated in a substudy with echocardiographic and biohumoral evaluation at baseline and at 12-month follow-up. The relations between biomarker concentrations and echocardiographic parameters with study endpoints in 1year, were analysed by a stepwise multivariable Cox model (entry criteria p < 0.5 and stay criteria p < 0.2). Results: The echocardiographic variables, cardiac markers and clinical variables considered in the statistical model indicated a higher concentration of NT-proBNP at baseline as the strongest factor related to time of first AF recurrence (HR 1.42; 95%CI 1.23-1.46), first CV hospitalization (HR 1.58; 95%CI 1.31-1.92) and increasing duration of recurrent AF (OR 2.16; 95%CI 1.52-3.08). Valsartan treatment was not related to clinical events. Conclusions: In patients in sinus rhythm with a history of AF a higher concentration of NT-proBNP at baseline was the strongest independent risk factor for first AF recurrence and its duration, and for the first hospital admission for cardiovascular reasons. Springer Science+Business Media New York, 2015 Atrial fibrillation nationallicence Echocardiography nationallicence Circulating biomarkers nationallicence Natriuretic peptides nationallicence Atrial fibrillation recurrence nationallicence Hospitalizations nationallicence Clinical trial nationallicence Staszewsky Lidia IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut Masson Serge IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut Barlera Simona IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut Disertori Marcello Ospedale Santa Chiara, Trento, Italy aut Boni Silvana Ospedale Civile San Biagio, Bovolone, Verona, Italy aut Bertoli Daniele Ospedale San Bartolomeo U.O, Santa Caterina, Sarzana, Italy aut Vriz Olga Ospedale San Antonio, San Daniele del Friuli, Italy aut Pasotti Elena Cardiocentro Ticino, Lugano, Switzerland aut Zeni Prisca Ospedale Santa Chiara, Trento, Italy aut Vago Tarcisio Ospedale Luigi Sacco, Milan, Italy aut Maggioni Aldo ANMCO Research Center, Florence, Italy aut Tognoni Gianni IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut Latini Roberto IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/6(2015-12-01), 551-561 0920-3206 29:6<551 2015 29 10557 https://doi.org/10.1007/s10557-015-6624-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6624-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Staszewsky Lidia IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut NATIONALLICENCE 700 1- Masson Serge IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut NATIONALLICENCE 700 1- Barlera Simona IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut NATIONALLICENCE 700 1- Disertori Marcello Ospedale Santa Chiara, Trento, Italy aut NATIONALLICENCE 700 1- Boni Silvana Ospedale Civile San Biagio, Bovolone, Verona, Italy aut NATIONALLICENCE 700 1- Bertoli Daniele Ospedale San Bartolomeo U.O, Santa Caterina, Sarzana, Italy aut NATIONALLICENCE 700 1- Vriz Olga Ospedale San Antonio, San Daniele del Friuli, Italy aut NATIONALLICENCE 700 1- Pasotti Elena Cardiocentro Ticino, Lugano, Switzerland aut NATIONALLICENCE 700 1- Zeni Prisca Ospedale Santa Chiara, Trento, Italy aut NATIONALLICENCE 700 1- Vago Tarcisio Ospedale Luigi Sacco, Milan, Italy aut NATIONALLICENCE 700 1- Maggioni Aldo ANMCO Research Center, Florence, Italy aut NATIONALLICENCE 700 1- Tognoni Gianni IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut NATIONALLICENCE 700 1- Latini Roberto IRCCS-Istituto di Ricerche Farmacologiche "MarioNegri”, Via Giuseppe La Masa, 19, 20156, Milan, Italy aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/6(2015-12-01), 551-561 0920-3206 29:6<551 2015 29 10557